Repligen Corp (NASDAQ:RGEN)
CAPS Rating:
A biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases of the central nervous system.
Growing the love for investing
A biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases of the central nervous system.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK